CPO-204

N/A

Report date: 2025/02/19 17:45:55

Base Information

Drug NameCPO-204
Drug Alias NameCPO-204
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-HER2Tubulin inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2Tubulin
Therapy Area/IndicationsCarcinoma, Transitional Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCSPC Pharmaceutical Group Ltd
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsCarcinoma, Transitional Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A